What is QMIS?
QMIS LLC develops innovative MRI-based quantitative and automated tools for improved diagnosis of prostate cancer (PCa), better patient outcomes.
QMIS has developed 'MrVIPro' (MR Virtual Pathology of the Prostate) which provides data similar to pathology based on compartmental analysis of Hybrid-Multidimensional MRI.
Provides volume fractions of three tissue components: lumen, storm, and epithelium
QMIS LLC- MrVIPro
MrVIPro is automatic image processing software that analyzes data from hybrid multidimensional MRI (HM-MRI). HM-MRI is a 2D matrix of diffusion-weighted and T2-weighted MRI data associated with each voxel.
MrVIPro analyzes the dependence of the measured ADC on TE and the dependence of the measured T2 on ‘b’ value to calculate volume fractions of lumen, stroma, and epithelium in the prostate.
MrVIPro provides Radiologists and researchers with accurate virtual pathology, including the volume fractions of lumen, stroma, and epithelium, and the ADC and T2 of each tissue compartment.
Prostate cancers have a higher than normal percentage of epithelium, and lower than normal percentage of stroma.
This product IS NOT INTENDED FOR CLINICAL USE AND IS NOT INTENDED TO DIAGNOSE PROSTATE CANCER.
FDA approval for use of MRVPro for measurement of prostate tissue composition is pending.